Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Call Transcript

And part of being more aggressive was to take advantage of a 14-week placebo-controlled period and where we wanted to get patients to their target dose as quickly as possible. The ongoing HL study is a year-long study, as you know, and therefore, there’s less urgency to get people to target dose, and we do know that it’s going a little more slowly and a little more just starting at a lower dose and going a little more slowly, increases the tolerability of the drug through that first four-week period, which is when they are at greatest risk for any of the GI complaints, which may cause people to struggle being on the drug. So that’s it, practical.

Operator: I’m not showing any further questions in the queue. I’d like to turn the call back over to David Meeker for any closing remarks.

David Meeker : Well, thanks, everyone, again for tuning in. Two calls in a short order here, and we look very much forward to our next one, fourth quarter earnings coming up in 2023. Have a good day.

Operator: And this concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone, have a great day.